Nektar Therapeutics
NKTR
143 hedge funds and large institutions have $124M invested in Nektar Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 49 increasing their positions, 35 reducing their positions, and 16 closing their positions.
4,260% more call options, than puts
Call options by funds: $218K | Put options by funds: $5K
40% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 35
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
4% more funds holding
Funds holding: 138 → 143 (+5)
0.3% less ownership
Funds ownership: 5.1% → 4.8% (-0.3%)
32% less capital invested
Capital invested by funds: $183M → $124M (-$59.4M)
Top Buyers
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.35M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.81M |
| 3 |
ACM
Altium Capital Management
New York
|
+$3.51M |
| 4 |
2L
22NW LP
Seattle,
Washington
|
+$2.58M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.82M |
Top Sellers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$16.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.71M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.23M |
| 4 |
SC
Shay Capital
New York
|
-$1.46M |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
-$1.43M |
NKTR Hedge Fund Activity: Q4 2024 in Review
143 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2024, worth a combined $124M — down 32% from $183M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NKTR positions and 16 closed out — a net gain of 5 holders — while 49 added to existing stakes and 35 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $4.35M. The largest seller was Deep Track Capital, cutting an estimated $16.4M.
- 143 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2024, up from 138 in Q3 2024.
- Funds reported $124M of Nektar Therapeutics stock for Q4 2024, down 32% quarter-over-quarter.
- 21 funds opened new Nektar Therapeutics positions in Q4 2024 and 16 closed out, a net change of +5 holders.
- The largest Nektar Therapeutics buyer in Q4 2024 was Nantahala Capital Management, an estimated $4.35M added.
- The largest Nektar Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $16.4M sold.
Based on aggregated 13F filings for Q4 2024.